Deals & business · first seen 5h ago, updated 5h ago
ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public listing.
Summary from Fierce Biotech - Biotech.
Coverage 1 article · 1 outlet
-
Fierce Biotech - BiotechADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans